GLP1R and chronic kidney disease: Subgroup analyses demonstrated that these benefits extended across diverse populations, including patients with stage 4 CKD, those stratified by age and sex, and individuals receiving diuretics, GLP-1 receptor agonists, or with baseline left ventricular hypertrophy.